We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabet Med 2019; 36: 1063–1071.
- Authors
Bain, S. C.; Bakhai, A.; Evans, M.; Green, A.; Menown, I.; Strain, W. D.
- Abstract
The article highlights the results of the Reseaching Cardiovascular (CV) Events With a Weekly INcretin in Diabetes (REWIND) trial. Topics covered include the criteria for participant recruitment into the REWIND trial, the reason dulaglutide is recommended as one of the second-line therapies for people with type 2 diabetes, and the cardiovascular outcomes seen with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- Subjects
UNITED Kingdom; CARDIOVASCULAR diseases risk factors; COST effectiveness; TYPE 2 diabetes; TREATMENT effectiveness; SODIUM-glucose cotransporters; GLUCAGON-like peptide-1 agonists
- Publication
Diabetic Medicine, 2020, Vol 37, Issue 8, p1405
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/dme.14172